The increase in operating expenses year-over-year was primarily driven by a $7.9 million increase in sales and marketing expenses, largely due to the addition of our AfloVest sales team and new hires added to our Lymphedema sales team, along with increased travel-related expenses as we return to normalized business activities, expenses related to our in-person national sales meeting held in April, and costs associated with new product introductions.

Aug 1, 2022 / CFO / receipt, needs a key / Brent Mullen, CFO | earnings call 2022-08-01 | transcript 585282ab-0c01-4640-9c12-61c92b62f036 | chars 13860-14313 | segment 14